Company intelligence / Profile preview

Hormosan Pharma

Frankfurt am Main, Hessen, Germanyhormosan.com ↗

Ownership: Private
Employees: ~94
Development stage: Other

Overview

Hormosan Pharma markets 61 products in Germany—54 of which are generics. The company does not develop its own new chemical entities but acquires finished developments or existing approvals for commercialization. Its focus areas include CNS/pain indications and sexual health. Recent growth has been driven by neurology sector products and new launches.

Therapeutic areas: NeurologyInfectious Diseases
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

Emtricitabin/Tenofovir Hormosan

Unknown

Partnerships

Not specifically disclosed; parent company Lupin has global partnerships.

Beyond the preview

Go deeper on Hormosan Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hormosan Pharma.

Explore the full profile